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THE HUMAN GENOME PROJECT: A
PUBLIC GOOD
Kathy Hudson'
THIS DISCUSSION WILL COVER the genome project
and what we do with technology transfer at the National Human
Genome Research Institute. The last couple of years have been
really remarkable both scientifically and sociologically.
It has been my observation that the Genome Project has
almost become a household word. My evidence for this is three-
fold. First of all, it is the appearance of cartoons about it in
newspapers and magazines that we pick up every day.
My second line of evidence is my mother, who lost track of
what I do when I went to graduate school in the early 80s-
though she was very proud of my accomplishments, she did not
understand them. On February 13th of this year, my mother
called me to congratulate me and my colleagues on having
rolled out the genome sequence, and she proceeded to engage
me in a very sophisticated discussion about genomics. I was so
puzzled. What happened?
It turns out that my mother had watched the press confer-
ence where we unveiled the sequence of the human genome and
its analysis not once, not twice, but three times on C-Span. I
think she learned quite a bit.
My third line of evidence comes from an experience I had
getting together for a drink with an old colleague of mine. We
were talking about the Genome Project and how things have
evolved; and the bartender and another guest jumped into our
conversation and they knew everything. It was remarkable.
So, in fact, I think we have become a household word.
While I think people's understanding is somewhat superficial, I
am hoping that that will provide the entree for a deeper under-
standing as we move forward and translate the Genome Project
into beneficial drugs and interventions. So the reason that we
t Ph.D., Assistant Director, National Human Genome Research Institute, Na-
tional Institutes of Health.
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are doing the Human Genome Project is that all disease has
some genetic component. That genetic component can range
from a very substantial one, as in so-called single gene disor-
ders, such as cystic fibrosis, to a very minor contribution, as in
AIDS, where there are genes that can render an individual resis-
tant to infection from HIV.
Most diseases fall in the intermediate category where there
are a large number of genes and a large number of complex en-
vironmental factors interacting with one another to increase dis-
ease risk. We need to understand that as a fundamental level in
order to allow the discovery of new drugs and interventions.
I will say in a sentence or two: What is the genome? The
genome is the sum of all the hereditary material within our
cells. The DNA is packaged into twenty-three packages called
chromosomes, imaginatively named "chromosome 1," "chromo-
some 2," "chromosome 3," and so forth.
All of the chromosomes are made up of DNA. If you took
the DNA from a single cell and stretched and laid it end to end,
it would stretch about six feet long. The DNA itself is made up
of four simple subunits. The DNA alphabet is four letters, A, C,
T and G. There are about 3.1 billion letters of DNA in the hu-
man genome. These letters contain instructions or genes that
control all of the fundamental biological processes of life. There
are the genes that make a liver cell a liver cell, a brain cell a
brain cell, and a single cell fertilized egg become a human
child. It is pretty remarkable stuff.
In the spelling of the DNA, the precise order of the letters
is also incredibly important. Like a computer code where the
order of the zeroes and ones is critical to the functioning of the
program, so is the order of the A's, C's, T's, then G's. So if you
have a G where there should be an A, that may create a protein
that misbehaves or does not function at all, and causes disease
or increases risk of disease.
So, the goal of the Human Genome Project is to map and
sequence the human genome and to identify and understand the
genes within it. Our best-known undertaking is having recently
deciphered the 3.1 billion base pairs in the human genetic code.
It was a pretty remarkable effort. In June of 1998, we had very
little of the human genome sequence. This was the international
effort involving sequencing centers around the world in what
was by far the largest international basic science collaboration
ever.
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The remarkable thing sociologically-and I hope somebody
studies this at some point-was taking a group of people who
had by their very nature been competitors ("I'm not going to
reveal my secrets because it will allow the other guy to compete
more effectively for grants") and to see a transition from com-
petition, to them coming together and working in a very organ-
ized and systematic effort to get the working draft of the human
genome completed.
In the steepest part of this slope here the genome centers
were producing 1,000 letters of DNA sequence every second of
every day, seven days a week.
We first started this ramp up in March of 1999 and in the
following fifteen months a lot was accomplished. In June 2000,
with that working draft in hand, there was a celebration. It was
sort of an odometer moment. We did not know much about what
the genome did, but we had all the letters or most of the letters.
So, there was a celebration, and a lot of fanfare, and headlines
across the country. And there was a celebration jointly with
Celera Genomics, who also independently developed their
working draft of the human genome.
So, in the intervening time, from June until February, really
the interesting part started. Now we had all of the A's, T's, C's
and G's, and we wanted to figure out what the words were, what
the sentences were, and to make meaning of them. So for me as
a molecular biologist and a geneticist, this is really the most ex-
citing time.
Using the best brains in biology and in computational biol-
ogy from around the world, six months were spent really scour-
ing that sequence to figure out what we could learn about age-
old mysteries in biology; and, in fact, we discovered new mys-
teries about biology.
Those results were published in Nature magazine in Febru-
ary. We were particularly pleased with the cover, which shows a
double helix section of DNA, but it is actually made up of a
mosaic of people's faces, people from around the world. That
seemed very fitting to us because the DNA sequence-the hu-
man genome-is about all of us. It is about the human species.
So we were very pleased with the cover.
But scientists do have a sense of humor, so as the analysis
was going forward and the paper was in review and all sorts of
stuff was happening, there were more e-mails about whose faces
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we wanted to insert on the cover than about the analysis of the
genome, at least for a couple of days. So we did include the
faces of Watson and Crick, who discovered the double helix
structure of DNA.
What did we find when we looked at the genome? Well, we
found a lot, and I will just mention a couple of things. The first
is that humans have fewer genes than were expected. The num-
ber that I have been using and we have been using at the Insti-
tute since 1995 was that humans have between 80,000 and
100,000 genes. It turns out that we have far fewer than that,
something in the range of 30,000 to 35,000 genes. That number
was independently arrived at by Celera Genomics, who feels
very confident that while that number may change by a little bit
up or down, it is not going to change dramatically. There are
those in the private sector who have invested quite heavily in
actually selling access, who are saying there are more than
35,000 genes, who are disputing this claim, but we feel quite
confident that it is solid.
So, what can we now do with all of these genes in hand?
One of the really amazing things that we can now do is look at
whether or not genes are turned on or turned off in any particu-
lar cell type or at any stage in pathology, in the development of
a tumor, in the development of an organ system, in people af-
fected by diabetes, and those who are unaffected by diabetes.
We can look at the expression of those genes in a single ex-
periment.
It used to take us ten years to find a gene and to look at its
expression. Now we can do it in a single experiment. In fact, the
roadblock is informatics-developing the computational power
to be able to analyze this data. So, on a little chip or microarray
you can look at the expression of 12,000 genes in a single ex-
periment, where a red spot indicates that that gene at that posi-
tion is on and a green spot indicates that that particular gene at
that position is off. It is an incredibly powerful technology; one
that was actually developed by a company that was founded
with a small business grant from NIH.
So, we'are not going to see drugs pouring into the market-
place as a direct consequence, within a year, because of the
Human Genome Project. There is a long development process,
and the NIH, and our institute in particular, are only involved in
the very beginnings of that pathway.
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So, being able to get to the end of this flow chart to develop
the preventive interventions, the new drug therapies, pharma-
cogenomic approaches in gene therapies, will require the private
sector to get involved, and it will take an indeterminate amount
of time for any given condition that you want to approach.
I want to give a quick example of the end points here.
Pharmacogenomics is the relatively new field of being able to
ascertain genetic profiles that dictate whether or not I will re-
spond to a particular drug; whether I will respond really well to
a particular drug, or whether or not, in fact, I will have an ad-
verse consequence to a particular pharmaceutical. That is going
to be very important to the future of the pharmaceutical industry
as we tailor drugs to individuals' genetic profiles.
The other end point here is the development of new drugs.
In sequencing the human genome, we identified a huge number
of new drug targets, previously unknown drug targets. So now,
as has been mentioned many times, not only is the biotechnol-
ogy industry heavily investing in this area, but also every major
pharmaceutical company has a major genomics component.
There are actually things starting to dribble out of the end
of this pipeline now, which is tremendously gratifying. One ex-
ample is a drug called Gleevec that is being produced by Novar-
tis to treat chronic myelogenous leukemia. Chronic myeloge-
nous leukemia is the result of a reciprocal translocation, where a
bit of one chromosome switches places with a bit of another
chromosome. When those bits of chromosomes change places,
parts of two genes at that junction point are fused. That fusion
protein misbehaves and causes the disease.
Novartis looked very carefully at that fusion protein and
developed a small molecule drug that would block its action.
Gleevec is in clinical trials now and is showing enormous posi-
tive effect, not only on leukemia, but also it is now being used
on solid tumors to great effect. In fact, a colleague of mine has
recently started taking Gleevec, and he is now back at work as a
result of treating a solid tumor with this drug.
There are a number of other such drugs that are entering
various stages of clinical trials, and gradually their number will
increase. I think we do have to counteract the hype but I think
there is great promise here and we should not lose sight of that.
So, the Genome Project goals are to provide the raw mate-
rials not only for biotechnology but also for the pharmaceutical
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industry. We have developed the genome sequence, the raw
fundamental information to be mined and used by industry, and
we have developed a catalog of sequence variants, places where
your genome varies from my genome, which are going to give
us information about disease risk and responsiveness to drugs.
We also develop bioinformatics tools and we study the ge-
nomes of other organisms, because they can tell us a lot about
our own. But, in fact, it is going to be the private sector that is
going to use this wealth of basic knowledge to develop new
medicines and bring them to market.
There has been discussion about how far into applied re-
search NIH and government funding reaches, and how far down
into basic research private sector funding reaches. NIH applied
research funding is relatively modest. The NIH spends a rela-
tively modest fraction of its budget on clinical research. At the
same time, genomics companies and pharmaceutical companies
are spending an increasing amount on basic, fundamental bio-
logical research. This intersection of research missions offers all
sorts of interesting opportunities for collaboration and coordina-
tion. But the private sector, the government, and academics try-
ing to work together must be mindful of the different cultures
and the different constraints on how they operate.
This slide shows the very familiar technology transfer cy-
cle. The National Human Genome Research Institute does have
an intramural program, a research program much like a fine
human genetics department. While it is one of the smallest of
the NIH Institutes, it has the third largest, most robust technol-
ogy transfer operation at the NIH, third only to the National
Cancer Institute and the National Institute of Allergy and Infec-
tious Diseases. We have an active cooperative research and de-
velopment agreement and technology transfer program.
Technology transfer has had an impact and there have been
some trends in the last few years. There certainly has been a
dramatic increase in academic, university patenting and there
has been an increase in industrial funding of basic research.
Interestingly, the number of academic scientific publications
that cite patents has gone up and the co-authorship between in-
dustrial and nonindustrial partners has also gone up. A by-
product of all of this is that the number of intellectual property
lawyers per dollar spent has also gone up.
There is an area of research in genomics which I think sort
of falls out of the traditional technology transfer cycle. Tradi-
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tionally in an academic environment scientists come up with a
great idea, develop that idea, file for a patent, license that inven-
tion to the private sector, and do a pass-off. What we are in-
creasingly finding in large-scale genomics is that there is a mo-
tivation for private sector and academic scientists to generate
the basic resources together.
NIH could generate the sequence of the human genome or
we could generate the sequence of cDNAs, copies of the genes
that are actually expressed, and we could encourage our investi-
gators to keep hold of that information and mine that informa-
tion until they reach the utility standards established by the PTO
before putting that out in the public domain.
We do not do that. In fact, as a condition of our grant
awards, we say that this data must be made immediately pub-
licly accessible. Harold Varmus, when he was director of the
NIH, initiated a program across the NIH to sequence so-called
cDNAs, copies of the expressed genes. Dr. Varmus sought and
obtained a declaration of exceptional circumstances that said
NIH could award grants and ask that the grantee institutions not
file patent applications on their inventions and put that data into
the public domain as an exception to Bayh-Dole.
Large public-private collaborations to generate basic fun-
damental raw sequence and genomic information are springing
up at an incredible rate. The first was the SNPs Consortium. An
SNP is a place where my genome varies from your genome, and
we want to develop a catalog of these variants. Nearly two mil-
lion of these places in the human genome that vary in sequence
among individuals have already been identified. All of that data
has been placed into the public domain.
The second public-private genomics collaboration is the
Mouse Sequencing Consortium. There are half a dozen or so
academic institutions involved in each of these consortia. Re-
cently we created the Rat Sequencing Network, again a public-
private-academic-government consortium to sequence the ge-
nome of the rat.
Then the last, which just recently filed as a 501(c)(3) or-
ganization, is the International Genomics Consortium, which is
an effort to obtain gene expression data on thousands and thou-
sands of cancer samples. People have raised questions about the
privacy of clinical medical records and information about tissue
samples. This consortium is attempting to balance those con-
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cerns. And, again, there will be no intellectual property on the
International Genome Consortium results.
I think that one of the critical things for both the academic
institutions and the corporate entities involved in genomics and
genetics is to be good citizens and to ensure that the public has
confidence and will be willing to use these products and partici-
pate in this research. One of the things standing in the way of
that confidence is fear of misuse of genetic information. A car-
toon from the New Yorker in 1996 was very prescient. A guy is
interviewing for a job and the employer says, "Very nice re-
sume. Please leave a sample of your DNA with my secretary on
your way out the door."
There was a story on "60 Minutes II" about the Burlington
Northern, Santa Fe Railroad case, which is really a call to action
for all of us to make sure that we have the right policies in place
for handling genetic information in the workplace. Are we ask-
ing for genetic information? Are we using genetic information
in the workplace?
The Brotherhood of the Maintenance of the Way Employ-
ees filed suit against Burlington Northern after employees who
had filed Workers Compensation claims based on carpal tunnel
syndrome were asked to come for a physical evaluation and
provide blood samples. And without their knowledge or con-
sent, those blood samples were subjected to genetic testing.
The clever wife of one of the workers learned of this, told
the union and the Equal Employment Opportunity Commission,
which then filed lawsuits. Burlington Northern said, "Oh, gee,
we didn't know we were doing this. This is a big mistake." It is
actually quite ironic. There is only a single publication in the
scientific literature indicating any correlation between the tests
that they were performing and the condition that they were
seeking to detect.
Burlington Northern settled with the union last week. In
their settlement agreement they promised that they would never
do genetic testing again. They also said they would destroy all
of the samples, which has raised a big brouhaha because some
of the employees who were tested said: "Wait a minute; that is
my evidence. If I want to file a case, my evidence is now gone."
But Burlington Northern said that they would destroy the sam-
ples, destroy the records, and that they would never do genetic
testing again unless it was agreed upon with the union.
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In an incredibly clever public relations move, Burlington
Northern said that as a part of the agreement, they now believe
that genetic information should not be used in the workplace as
a condition of hiring, firing, assignments, or any other em-
ployee-related decisionmaking, and that they will begin within
thirty days of signing the agreement to lobby the Congress and
the White House to enact legislation to prevent the misuse of
genetic information in the workplace.

